[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fIp6KGA22vzotjxuuLw3TjNxkO8vSLrXt4KxgMxd9lvc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"Centre Georges Francois Leclerc",[4],75,false,28,1,23839,16,44,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Breast Cancer",11,{"name":18,"count":19},"Cancer",6,{"name":21,"count":22},"Metastatic Colorectal Cancer",4,{"name":24,"count":25},"Colorectal Cancer",3,{"name":27,"count":25},"Prostate Cancer",{"name":29,"count":25},"Glioblastoma",{"name":31,"count":32},"Metastatic Pancreatic Cancer",2,{"name":34,"count":32},"Non-Small Cell Lung Cancer",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03795311","Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)","2023-01-16","FOLFIRINOX Bevacizumab",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05783908","Impact of Non-magnetic Screen Respiratory Self-guidance During MRI-guided Radiotherapy Sessions for Mobile Lesions","2025-09-27","With non-magnetic screen",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05695313","Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL","2026-06-30","OnLife®",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05201352","Evaluation of Efficacy of Trifluridine\u002FTipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine\u002FTipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine","2026-10-13","trifluridine\u002Ftipiracil + XB2001",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07587827","Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer","2027-05-01","Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT04169841","Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment","2027-08-10","olaparib, durvalumab, tremelimumab",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT04141462","EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer","2028-04-07","blood sample",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT05937906","Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 \u003C 50 %.","2028-05-25","Phase I - Mirdametinib - Level 1",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04614480","Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine","2028-09-02","Exome analysis",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT05988814","Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy","2029-07-24","FOLFIRINOX treatment",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,117,135,156,177,198,222,240,258,276,294,321,341,362,385,425,447,471,497,524,542,560,584,611,629,652,677,703,721,751,769,793,818,855,881,899,924,949,967,993],{"intervention":55,"totalTrials":9,"cells":95},{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":111,"PHASE4":113,"NA":115},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":9,"soonestReadout":54},[103],{"nctId":52,"briefTitle":53,"status":104,"phases":105,"primaryCompletion":54,"completion":54,"start":106,"enrollment":107,"conditions":108,"interventions":109},"ACTIVE_NOT_RECRUITING",[88,89],"2022-10-13",160,[21],[55,110],"trifluridine\u002Ftipiracil + placebo",{"trials":112,"activeCount":98},[],{"trials":114,"activeCount":98},[],{"trials":116,"activeCount":98},[],{"intervention":110,"totalTrials":9,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":129,"PHASE4":131,"NA":133},{"trials":120,"activeCount":98},[],{"trials":122,"activeCount":98},[],{"trials":124,"activeCount":9,"soonestReadout":54},[125],{"nctId":52,"briefTitle":53,"status":104,"phases":126,"primaryCompletion":54,"completion":54,"start":106,"enrollment":107,"conditions":127,"interventions":128},[88,89],[21],[55,110],{"trials":130,"activeCount":98},[],{"trials":132,"activeCount":98},[],{"trials":134,"activeCount":98},[],{"intervention":85,"totalTrials":9,"cells":136},{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":150,"PHASE4":152,"NA":154},{"trials":138,"activeCount":98},[],{"trials":140,"activeCount":98},[],{"trials":142,"activeCount":9,"soonestReadout":84},[143],{"nctId":82,"briefTitle":83,"status":144,"phases":145,"primaryCompletion":84,"completion":84,"start":146,"enrollment":147,"conditions":148,"interventions":149},"RECRUITING",[89],"2024-01-24",90,[31],[85],{"trials":151,"activeCount":98},[],{"trials":153,"activeCount":98},[],{"trials":155,"activeCount":98},[],{"intervention":80,"totalTrials":9,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":171,"PHASE4":173,"NA":175},{"trials":159,"activeCount":98},[],{"trials":161,"activeCount":98},[],{"trials":163,"activeCount":9,"soonestReadout":79},[164],{"nctId":77,"briefTitle":78,"status":144,"phases":165,"primaryCompletion":79,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":170},[89],"2032-09-02","2020-08-25",7976,[18],[80],{"trials":172,"activeCount":98},[],{"trials":174,"activeCount":98},[],{"trials":176,"activeCount":98},[],{"intervention":65,"totalTrials":9,"cells":178},{"EARLY_PHASE1":179,"PHASE1":181,"PHASE2":183,"PHASE3":192,"PHASE4":194,"NA":196},{"trials":180,"activeCount":98},[],{"trials":182,"activeCount":98},[],{"trials":184,"activeCount":9,"soonestReadout":64},[185],{"nctId":62,"briefTitle":63,"status":104,"phases":186,"primaryCompletion":64,"completion":64,"start":187,"enrollment":188,"conditions":189,"interventions":191},[89],"2020-02-10",270,[190],"Immunotherapy",[65],{"trials":193,"activeCount":98},[],{"trials":195,"activeCount":98},[],{"trials":197,"activeCount":98},[],{"intervention":75,"totalTrials":9,"cells":199},{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":216,"PHASE4":218,"NA":220},{"trials":201,"activeCount":98},[],{"trials":203,"activeCount":98},[],{"trials":205,"activeCount":9,"soonestReadout":74},[206],{"nctId":72,"briefTitle":73,"status":144,"phases":207,"primaryCompletion":74,"completion":74,"start":208,"enrollment":209,"conditions":210,"interventions":211},[88,89],"2024-07-30",24,[34],[75,212,213,214,215],"Phase II - Mirdametinib","Phase I - Mirdametinib - Level 2","Phase I - Mirdametinib - Level 3","Phase I - Mirdametinib - Level 4",{"trials":217,"activeCount":98},[],{"trials":219,"activeCount":98},[],{"trials":221,"activeCount":98},[],{"intervention":212,"totalTrials":9,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":234,"PHASE4":236,"NA":238},{"trials":225,"activeCount":98},[],{"trials":227,"activeCount":98},[],{"trials":229,"activeCount":9,"soonestReadout":74},[230],{"nctId":72,"briefTitle":73,"status":144,"phases":231,"primaryCompletion":74,"completion":74,"start":208,"enrollment":209,"conditions":232,"interventions":233},[88,89],[34],[75,212,213,214,215],{"trials":235,"activeCount":98},[],{"trials":237,"activeCount":98},[],{"trials":239,"activeCount":98},[],{"intervention":213,"totalTrials":9,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":252,"PHASE4":254,"NA":256},{"trials":243,"activeCount":98},[],{"trials":245,"activeCount":98},[],{"trials":247,"activeCount":9,"soonestReadout":74},[248],{"nctId":72,"briefTitle":73,"status":144,"phases":249,"primaryCompletion":74,"completion":74,"start":208,"enrollment":209,"conditions":250,"interventions":251},[88,89],[34],[75,212,213,214,215],{"trials":253,"activeCount":98},[],{"trials":255,"activeCount":98},[],{"trials":257,"activeCount":98},[],{"intervention":214,"totalTrials":9,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":270,"PHASE4":272,"NA":274},{"trials":261,"activeCount":98},[],{"trials":263,"activeCount":98},[],{"trials":265,"activeCount":9,"soonestReadout":74},[266],{"nctId":72,"briefTitle":73,"status":144,"phases":267,"primaryCompletion":74,"completion":74,"start":208,"enrollment":209,"conditions":268,"interventions":269},[88,89],[34],[75,212,213,214,215],{"trials":271,"activeCount":98},[],{"trials":273,"activeCount":98},[],{"trials":275,"activeCount":98},[],{"intervention":215,"totalTrials":9,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":288,"PHASE4":290,"NA":292},{"trials":279,"activeCount":98},[],{"trials":281,"activeCount":98},[],{"trials":283,"activeCount":9,"soonestReadout":74},[284],{"nctId":72,"briefTitle":73,"status":144,"phases":285,"primaryCompletion":74,"completion":74,"start":208,"enrollment":209,"conditions":286,"interventions":287},[88,89],[34],[75,212,213,214,215],{"trials":289,"activeCount":98},[],{"trials":291,"activeCount":98},[],{"trials":293,"activeCount":98},[],{"intervention":295,"totalTrials":9,"cells":296},"Lipidomic analyses",{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":315,"PHASE4":317,"NA":319},{"trials":298,"activeCount":98},[],{"trials":300,"activeCount":98},[],{"trials":302,"activeCount":9,"soonestReadout":308},[303],{"nctId":304,"briefTitle":305,"status":306,"phases":307,"primaryCompletion":308,"completion":308,"start":309,"enrollment":310,"conditions":311,"interventions":314},"NCT06944548","Evaluation of the Effect of Adapted Physical Activity on the Modification of Lipid Metabolism During Chemotherapy for Metastatic COLorectal Cancer","NOT_YET_RECRUITING",[89],"2030-06-01","2025-06-01",54,[312,313],"Metastatic Colorectal Cancer (CRC)","Volunteer Subjects",[295],{"trials":316,"activeCount":98},[],{"trials":318,"activeCount":98},[],{"trials":320,"activeCount":98},[],{"intervention":50,"totalTrials":9,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":335,"PHASE4":337,"NA":339},{"trials":324,"activeCount":98},[],{"trials":326,"activeCount":98},[],{"trials":328,"activeCount":9,"soonestReadout":49},[329],{"nctId":47,"briefTitle":48,"status":144,"phases":330,"primaryCompletion":49,"completion":49,"start":331,"enrollment":332,"conditions":333,"interventions":334},[89],"2024-04-12",60,[15],[50],{"trials":336,"activeCount":98},[],{"trials":338,"activeCount":98},[],{"trials":340,"activeCount":98},[],{"intervention":40,"totalTrials":9,"cells":342},{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":356,"PHASE4":358,"NA":360},{"trials":344,"activeCount":98},[],{"trials":346,"activeCount":98},[],{"trials":348,"activeCount":9,"soonestReadout":39},[349],{"nctId":37,"briefTitle":38,"status":104,"phases":350,"primaryCompletion":39,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":355},[88,89],"2025-07-16","2018-11-07",32,[24],[40],{"trials":357,"activeCount":98},[],{"trials":359,"activeCount":98},[],{"trials":361,"activeCount":98},[],{"intervention":60,"totalTrials":9,"cells":363},{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":377,"PHASE3":379,"PHASE4":381,"NA":383},{"trials":365,"activeCount":98},[],{"trials":367,"activeCount":9,"soonestReadout":59},[368],{"nctId":57,"briefTitle":58,"status":306,"phases":369,"primaryCompletion":59,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":376},[88],"2031-05-01","2026-11-01",77,[312,374,31,375],"Locally Advanced Colorectal Cancer","Locally Advanced Pancreatic Cancer",[60],{"trials":378,"activeCount":98},[],{"trials":380,"activeCount":98},[],{"trials":382,"activeCount":98},[],{"trials":384,"activeCount":98},[],{"intervention":70,"totalTrials":25,"cells":386},{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":393,"PHASE4":395,"NA":397},{"trials":388,"activeCount":98},[],{"trials":390,"activeCount":98},[],{"trials":392,"activeCount":98},[],{"trials":394,"activeCount":98},[],{"trials":396,"activeCount":98},[],{"trials":398,"activeCount":9,"soonestReadout":69},[399,406,416],{"nctId":67,"briefTitle":68,"status":144,"phases":400,"primaryCompletion":69,"completion":69,"start":401,"enrollment":402,"conditions":403,"interventions":405},[92],"2019-10-07",613,[18,404],"Genetic Predisposition",[70],{"nctId":407,"briefTitle":408,"status":409,"phases":410,"primaryCompletion":411,"completion":411,"start":412,"enrollment":332,"conditions":413,"interventions":415},"NCT03625791","Validation of a Genetic Signature to Predict the Development of Sarcomas","COMPLETED",[],"2022-06-19","2018-06-19",[414],"Genetic Signature in Development of Sarcomas",[70],{"nctId":417,"briefTitle":418,"status":409,"phases":419,"primaryCompletion":420,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":424},"NCT04517097","Study of the Specific Seroprevalence of SARS-CoV-2 in a Sample of Patients and Salaried Staff From a French Anti-cancer Center at the End of the Containment Period of the SARS-CoV-2 Pandemic",[],"2020-06-30","2020-05-12",1680,[18],[70],{"intervention":45,"totalTrials":9,"cells":426},{"EARLY_PHASE1":427,"PHASE1":429,"PHASE2":431,"PHASE3":433,"PHASE4":435,"NA":437},{"trials":428,"activeCount":98},[],{"trials":430,"activeCount":98},[],{"trials":432,"activeCount":98},[],{"trials":434,"activeCount":98},[],{"trials":436,"activeCount":98},[],{"trials":438,"activeCount":9,"soonestReadout":44},[439],{"nctId":42,"briefTitle":43,"status":144,"phases":440,"primaryCompletion":44,"completion":44,"start":441,"enrollment":442,"conditions":443,"interventions":446},[92],"2023-10-16",100,[444,445],"Patient With Radiotherapy (Linac MRI)","Mobile Cancerous Lesion",[45],{"intervention":448,"totalTrials":9,"cells":449},"Pemetrexed",{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":458,"NA":469},{"trials":451,"activeCount":98},[],{"trials":453,"activeCount":98},[],{"trials":455,"activeCount":98},[],{"trials":457,"activeCount":98},[],{"trials":459,"activeCount":98},[460],{"nctId":461,"briefTitle":462,"status":409,"phases":463,"primaryCompletion":464,"completion":464,"start":465,"enrollment":16,"conditions":466,"interventions":468},"NCT03607149","Pemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation Strategies",[91],"2020-02-20","2017-04-06",[467],"Non-small Cell Lung Cancer",[448],{"trials":470,"activeCount":98},[],{"intervention":472,"totalTrials":9,"cells":473},"chemotherapy: FOLFOX 4",{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":493,"NA":495},{"trials":475,"activeCount":98},[],{"trials":477,"activeCount":98},[],{"trials":479,"activeCount":98},[],{"trials":481,"activeCount":98},[482],{"nctId":483,"briefTitle":484,"status":409,"phases":485,"primaryCompletion":486,"completion":487,"start":488,"enrollment":489,"conditions":490,"interventions":492},"NCT01348217","Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus",[89,90],"2011-06-07","2018-12-17","2011-05-06",196,[491],"Esophageal Cancer",[472],{"trials":494,"activeCount":98},[],{"trials":496,"activeCount":98},[],{"intervention":498,"totalTrials":9,"cells":499},"oxaliplatin",{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":518,"PHASE4":520,"NA":522},{"trials":501,"activeCount":98},[],{"trials":503,"activeCount":98},[],{"trials":505,"activeCount":98},[506],{"nctId":507,"briefTitle":508,"status":409,"phases":509,"primaryCompletion":510,"completion":511,"start":510,"enrollment":512,"conditions":513,"interventions":515},"NCT01348412","Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure",[89],"2010-12-15","2018-04-18",31,[24,514],"Liver Metastases",[498,516,517],"raltitrexed","other intravenous chemotherapy drugs",{"trials":519,"activeCount":98},[],{"trials":521,"activeCount":98},[],{"trials":523,"activeCount":98},[],{"intervention":516,"totalTrials":9,"cells":525},{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":536,"PHASE4":538,"NA":540},{"trials":527,"activeCount":98},[],{"trials":529,"activeCount":98},[],{"trials":531,"activeCount":98},[532],{"nctId":507,"briefTitle":508,"status":409,"phases":533,"primaryCompletion":510,"completion":511,"start":510,"enrollment":512,"conditions":534,"interventions":535},[89],[24,514],[498,516,517],{"trials":537,"activeCount":98},[],{"trials":539,"activeCount":98},[],{"trials":541,"activeCount":98},[],{"intervention":517,"totalTrials":9,"cells":543},{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":554,"PHASE4":556,"NA":558},{"trials":545,"activeCount":98},[],{"trials":547,"activeCount":98},[],{"trials":549,"activeCount":98},[550],{"nctId":507,"briefTitle":508,"status":409,"phases":551,"primaryCompletion":510,"completion":511,"start":510,"enrollment":512,"conditions":552,"interventions":553},[89],[24,514],[498,516,517],{"trials":555,"activeCount":98},[],{"trials":557,"activeCount":98},[],{"trials":559,"activeCount":98},[],{"intervention":561,"totalTrials":9,"cells":562},"Androgen deprivation",{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":578,"PHASE4":580,"NA":582},{"trials":564,"activeCount":98},[],{"trials":566,"activeCount":98},[],{"trials":568,"activeCount":98},[569],{"nctId":570,"briefTitle":571,"status":572,"phases":573,"primaryCompletion":574,"start":575,"enrollment":8,"conditions":576,"interventions":577},"NCT01704027","Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer","TERMINATED",[89],"2014-03","2012-10",[27],[561],{"trials":579,"activeCount":98},[],{"trials":581,"activeCount":98},[],{"trials":583,"activeCount":98},[],{"intervention":585,"totalTrials":9,"cells":586},"Avastin + Campto \u002F radiotherapy + Temodal + Avastin",{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":605,"PHASE4":607,"NA":609},{"trials":588,"activeCount":98},[],{"trials":590,"activeCount":98},[],{"trials":592,"activeCount":98},[593],{"nctId":594,"briefTitle":595,"status":409,"phases":596,"primaryCompletion":597,"completion":598,"start":599,"enrollment":600,"conditions":601,"interventions":603},"NCT01022918","Evaluation of the Irinotecan\u002FBevacizumab Association for Naive Unresectable Glioblastoma",[89],"2010-07","2011-01","2009-01",134,[602],"Naive Unresectable Glioblastoma",[585,604],"Temodal\u002Fradiotherapy",{"trials":606,"activeCount":98},[],{"trials":608,"activeCount":98},[],{"trials":610,"activeCount":98},[],{"intervention":604,"totalTrials":9,"cells":612},{"EARLY_PHASE1":613,"PHASE1":615,"PHASE2":617,"PHASE3":623,"PHASE4":625,"NA":627},{"trials":614,"activeCount":98},[],{"trials":616,"activeCount":98},[],{"trials":618,"activeCount":98},[619],{"nctId":594,"briefTitle":595,"status":409,"phases":620,"primaryCompletion":597,"completion":598,"start":599,"enrollment":600,"conditions":621,"interventions":622},[89],[602],[585,604],{"trials":624,"activeCount":98},[],{"trials":626,"activeCount":98},[],{"trials":628,"activeCount":98},[],{"intervention":630,"totalTrials":9,"cells":631},"ANAKINRA",{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":646,"PHASE4":648,"NA":650},{"trials":633,"activeCount":98},[],{"trials":635,"activeCount":98},[],{"trials":637,"activeCount":98},[638],{"nctId":639,"briefTitle":640,"status":409,"phases":641,"primaryCompletion":642,"completion":643,"start":642,"enrollment":353,"conditions":644,"interventions":645},"NCT02090101","Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer",[89],"2014-10-10","2017-05-15",[21],[630],{"trials":647,"activeCount":98},[],{"trials":649,"activeCount":98},[],{"trials":651,"activeCount":98},[],{"intervention":653,"totalTrials":9,"cells":654},"Durvalumab, Tremelimumab and ,FOLFOX",{"EARLY_PHASE1":655,"PHASE1":657,"PHASE2":659,"PHASE3":671,"PHASE4":673,"NA":675},{"trials":656,"activeCount":98},[],{"trials":658,"activeCount":98},[],{"trials":660,"activeCount":98},[661],{"nctId":662,"briefTitle":663,"status":409,"phases":664,"primaryCompletion":665,"completion":665,"start":666,"enrollment":667,"conditions":668,"interventions":670},"NCT03202758","Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC",[88,89],"2023-01-09","2017-08-29",57,[669],"Colorectal Cancer Metastatic",[653],{"trials":672,"activeCount":98},[],{"trials":674,"activeCount":98},[],{"trials":676,"activeCount":98},[],{"intervention":678,"totalTrials":9,"cells":679},"lapatinib",{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":697,"PHASE4":699,"NA":701},{"trials":681,"activeCount":98},[],{"trials":683,"activeCount":98},[],{"trials":685,"activeCount":98},[686],{"nctId":687,"briefTitle":688,"status":409,"phases":689,"primaryCompletion":690,"start":691,"enrollment":692,"conditions":693,"interventions":695},"NCT01044485","Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer",[88,89],"2011-11","2008-11",17,[694],"Metastatic Breast Cancer",[678,696],"docetaxel",{"trials":698,"activeCount":98},[],{"trials":700,"activeCount":98},[],{"trials":702,"activeCount":98},[],{"intervention":696,"totalTrials":9,"cells":704},{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":715,"PHASE4":717,"NA":719},{"trials":706,"activeCount":98},[],{"trials":708,"activeCount":98},[],{"trials":710,"activeCount":98},[711],{"nctId":687,"briefTitle":688,"status":409,"phases":712,"primaryCompletion":690,"start":691,"enrollment":692,"conditions":713,"interventions":714},[88,89],[694],[678,696],{"trials":716,"activeCount":98},[],{"trials":718,"activeCount":98},[],{"trials":720,"activeCount":98},[],{"intervention":722,"totalTrials":9,"cells":723},"Atezolizumab 60 MG\u002F1 ML Intravenous Solution [TECENTRIQ]",{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":743,"PHASE3":745,"PHASE4":747,"NA":749},{"trials":725,"activeCount":98},[],{"trials":727,"activeCount":98},[728],{"nctId":729,"briefTitle":730,"status":731,"phases":732,"primaryCompletion":733,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":741},"NCT05259319","Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)","UNKNOWN",[88],"2024-12-05","2022-12-05",92,[737,738,739,740],"Metastatic Non Small Cell Lung Cancer","Metastatic Bladder Cancer","Metastatic Renal Cell Carcinoma","Metastatic Head and Neck Cancer",[722,742],"Tiragolumab",{"trials":744,"activeCount":98},[],{"trials":746,"activeCount":98},[],{"trials":748,"activeCount":98},[],{"trials":750,"activeCount":98},[],{"intervention":742,"totalTrials":9,"cells":752},{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":761,"PHASE3":763,"PHASE4":765,"NA":767},{"trials":754,"activeCount":98},[],{"trials":756,"activeCount":98},[757],{"nctId":729,"briefTitle":730,"status":731,"phases":758,"primaryCompletion":733,"completion":733,"start":734,"enrollment":735,"conditions":759,"interventions":760},[88],[737,738,739,740],[722,742],{"trials":762,"activeCount":98},[],{"trials":764,"activeCount":98},[],{"trials":766,"activeCount":98},[],{"trials":768,"activeCount":98},[],{"intervention":770,"totalTrials":9,"cells":771},"temozolomide",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":785,"PHASE3":787,"PHASE4":789,"NA":791},{"trials":773,"activeCount":98},[],{"trials":775,"activeCount":98},[776],{"nctId":777,"briefTitle":778,"status":409,"phases":779,"primaryCompletion":780,"start":781,"enrollment":782,"conditions":783,"interventions":784},"NCT01043536","Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults",[88],"2012-01","2009-09",10,[29],[770],{"trials":786,"activeCount":98},[],{"trials":788,"activeCount":98},[],{"trials":790,"activeCount":98},[],{"trials":792,"activeCount":98},[],{"intervention":794,"totalTrials":9,"cells":795},"CTC",{"EARLY_PHASE1":796,"PHASE1":808,"PHASE2":810,"PHASE3":812,"PHASE4":814,"NA":816},{"trials":797,"activeCount":98},[798],{"nctId":799,"briefTitle":800,"status":572,"phases":801,"primaryCompletion":802,"completion":803,"start":802,"enrollment":804,"conditions":805,"interventions":807},"NCT01380795","Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas",[87],"2011-03-09","2019-06",30,[806],"Non-small Cell Lung Cancer Metastatic",[794],{"trials":809,"activeCount":98},[],{"trials":811,"activeCount":98},[],{"trials":813,"activeCount":98},[],{"trials":815,"activeCount":98},[],{"trials":817,"activeCount":98},[],{"intervention":819,"totalTrials":32,"cells":820},"Blood samples",{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":827,"PHASE4":829,"NA":831},{"trials":822,"activeCount":98},[],{"trials":824,"activeCount":98},[],{"trials":826,"activeCount":98},[],{"trials":828,"activeCount":98},[],{"trials":830,"activeCount":98},[],{"trials":832,"activeCount":98},[833,843],{"nctId":834,"briefTitle":835,"status":409,"phases":836,"primaryCompletion":837,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":842},"NCT03800121","Study of Exosomes in Monitoring Patients With Sarcoma (EXOSARC)",[],"2024-11-19","2018-11-19",34,[841],"Sarcoma",[819],{"nctId":844,"briefTitle":845,"status":731,"phases":846,"primaryCompletion":847,"completion":848,"start":849,"enrollment":850,"conditions":851,"interventions":853},"NCT04675320","Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors",[],"2022-11-10","2024-11-10","2020-07-07",50,[852],"Ovarian Cancer",[854],"blood samples",{"intervention":856,"totalTrials":9,"cells":857},"Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF",{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":864,"PHASE4":866,"NA":868},{"trials":859,"activeCount":98},[],{"trials":861,"activeCount":98},[],{"trials":863,"activeCount":98},[],{"trials":865,"activeCount":98},[],{"trials":867,"activeCount":98},[],{"trials":869,"activeCount":98},[870],{"nctId":871,"briefTitle":872,"status":409,"phases":873,"primaryCompletion":874,"completion":874,"start":875,"enrollment":876,"conditions":877,"interventions":879},"NCT05296317","Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration",[92],"2025-09-26","2022-09-02",97,[878],"Localized Breast Cancer",[856,880],"Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF",{"intervention":880,"totalTrials":9,"cells":882},{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":889,"PHASE4":891,"NA":893},{"trials":884,"activeCount":98},[],{"trials":886,"activeCount":98},[],{"trials":888,"activeCount":98},[],{"trials":890,"activeCount":98},[],{"trials":892,"activeCount":98},[],{"trials":894,"activeCount":98},[895],{"nctId":871,"briefTitle":872,"status":409,"phases":896,"primaryCompletion":874,"completion":874,"start":875,"enrollment":876,"conditions":897,"interventions":898},[92],[878],[856,880],{"intervention":900,"totalTrials":9,"cells":901},"Collection of stool and serum samples",{"EARLY_PHASE1":902,"PHASE1":904,"PHASE2":906,"PHASE3":908,"PHASE4":910,"NA":912},{"trials":903,"activeCount":98},[],{"trials":905,"activeCount":98},[],{"trials":907,"activeCount":98},[],{"trials":909,"activeCount":98},[],{"trials":911,"activeCount":98},[],{"trials":913,"activeCount":98},[914],{"nctId":915,"briefTitle":916,"status":409,"phases":917,"primaryCompletion":918,"completion":919,"start":918,"enrollment":920,"conditions":921,"interventions":923},"NCT03196609","Characteristics of the Intestinal Microbiota in Patients With Cancer",[92],"2017-02-06","2018-07-05",69,[922],"Oncology",[900],{"intervention":925,"totalTrials":9,"cells":926},"serology and ELISPOT test",{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":933,"PHASE4":935,"NA":937},{"trials":928,"activeCount":98},[],{"trials":930,"activeCount":98},[],{"trials":932,"activeCount":98},[],{"trials":934,"activeCount":98},[],{"trials":936,"activeCount":98},[],{"trials":938,"activeCount":98},[939],{"nctId":940,"briefTitle":941,"status":409,"phases":942,"primaryCompletion":943,"completion":943,"start":944,"enrollment":945,"conditions":946,"interventions":947},"NCT04935528","Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center",[92],"2022-01-26","2021-06-02",539,[18],[925,948],"serology",{"intervention":948,"totalTrials":9,"cells":950},{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":952,"activeCount":98},[],{"trials":954,"activeCount":98},[],{"trials":956,"activeCount":98},[],{"trials":958,"activeCount":98},[],{"trials":960,"activeCount":98},[],{"trials":962,"activeCount":98},[963],{"nctId":940,"briefTitle":941,"status":409,"phases":964,"primaryCompletion":943,"completion":943,"start":944,"enrollment":945,"conditions":965,"interventions":966},[92],[18],[925,948],{"intervention":968,"totalTrials":9,"cells":969},"tumor genetic predisposition to develop sarcoma assessment",{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":974,"PHASE3":976,"PHASE4":978,"NA":980},{"trials":971,"activeCount":98},[],{"trials":973,"activeCount":98},[],{"trials":975,"activeCount":98},[],{"trials":977,"activeCount":98},[],{"trials":979,"activeCount":98},[],{"trials":981,"activeCount":98},[982],{"nctId":983,"briefTitle":984,"status":409,"phases":985,"primaryCompletion":986,"completion":987,"start":988,"enrollment":989,"conditions":990,"interventions":992},"NCT01504360","Predictive Study of Radiation Induced Sarcoma",[92],"2016-07","2017-06","2011-12",360,[991],"Radiation Induced Sarcoma",[968,968],{"intervention":994,"totalTrials":9,"cells":995},"Neoadjuvant therapy",{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1004,"NA":1006},{"trials":997,"activeCount":98},[],{"trials":999,"activeCount":98},[],{"trials":1001,"activeCount":98},[],{"trials":1003,"activeCount":98},[],{"trials":1005,"activeCount":98},[],{"trials":1007,"activeCount":98},[1008],{"nctId":1009,"briefTitle":1010,"status":731,"phases":1011,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":1015,"interventions":1017},"NCT04031612","Neoadjuvant Database",[],"2024-09","2009-09-09",2000,[1016],"Neoadjuvant Treatment in Breast Cancer",[994]]